Journal article
Durability of Response of UGN-101: Longitudinal Follow Up of Multicenter Study
Urologic oncology, Vol.43(6), pp.391.e11-391.e20
06/2025
DOI: 10.1016/j.urolonc.2024.12.279
PMID: 39837708
Abstract
•UGN-101 treatment has excellent durability in those initially respond to the treatment.•Durability not impacted by instillation technique, adjuvant vs. chemoablative, initial size•Caution with UGN-101 in high-grade tumors, responders still at high progression risk
: UGN-101, a reverse thermal mitomycin gel for upper tract instillation, recently became the first FDA approved treatment for upper tract urothelial carcinoma (UTUC). However, the durability of UGN-101 treatment has not been well described. Here we present long term outcomes from our muli-institutional cohort for patients who initially responded to treatment.
: We identified patients from a multi-institutional database with UTUC who had a negative endoscopic evaluation following either adjuvant or chemoablative UGN-101 induction. Recurrence and progression data for those patients was reviewed. Kaplan-Meier survival analysis was performed, stratified by relevant clinical features.
: We identified 56 renal units that met the inclusion criteria of which 93% had low-grade disease while 4 cases had high-grade UTUC. With a median follow-up of 23.5 months, 21.4% of renal units experienced a recurrence, with 65% of renal units recurrence-free at 36 months. Three patients experienced eventual progression of disease leading to mortality, however only one of these patients had presumed low-grade UTUC and did not undergo nephroureterectomy on recurrence due to solitary kidney.
: UGN-101 treatment has excellent durability in patients who initially respond to the treatment. Further study is needed to better understand the long term outcomes of this novel therapy and also the risks/benefits of maintenance therapy in this setting. Caution should be used in patients with high-grade disease who appear to be at higher risk of relapse and death despite initial response.
Details
- Title: Subtitle
- Durability of Response of UGN-101: Longitudinal Follow Up of Multicenter Study
- Creators
- Solomon L Woldu - The University of Texas Southwestern Medical CenterDaniel Igel - The University of Texas MD Anderson Cancer CenterBrett Johnson - The University of Texas Southwestern Medical CenterKatie S Murray - NYU Langone HealthHiroko Miyagi - Moffitt Cancer CenterWade Sexton - Moffitt Cancer CenterIsamu Tachibana - The University of Texas Southwestern Medical CenterHristos Kaimakliotis - Indiana University IndianapolisJoseph Jacob - SUNY Upstate Medical UniversityRian Dickstein - University of Maryland Medical CenterJennifer LinehanAlan Nieder - Mount Sinai Medical CenterMarc A Bjurlin - University of North Carolina at Chapel HillDaniel Heidenberg - Mayo Clinic HospitalMitchell Humphreys - Mayo Clinic HospitalSaum Ghodoussipour - Rutgers, The State University of New JerseyMarcus L Quek - Loyola University Medical CenterMichael O'Donnell - University of IowaBrian H Eisner - Massachusetts General HospitalAdam S Feldman - Massachusetts General HospitalSurena F Matin - The University of Texas MD Anderson Cancer CenterYair Lotan - The University of Texas Southwestern Medical Center
- Resource Type
- Journal article
- Publication Details
- Urologic oncology, Vol.43(6), pp.391.e11-391.e20
- DOI
- 10.1016/j.urolonc.2024.12.279
- PMID
- 39837708
- NLM abbreviation
- Urol Oncol
- ISSN
- 1078-1439
- eISSN
- 1873-2496
- Publisher
- Elsevier Inc; NEW YORK
- Language
- English
- Electronic publication date
- 01/20/2025
- Date published
- 06/2025
- Academic Unit
- Urology
- Record Identifier
- 9984775012902771
Metrics
5 Record Views